Association Between Long-Term Proton Pump Inhibitor Use and the Risk of Osteoporotic Fractures
- 1Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, P.O. Box 653, Beer-Sheva 8410501, Israel
Abstract
Proton pump inhibitors (PPIs) are among the most widely prescribed medications and remain a cornerstone in the treatment of acid-related gastrointestinal disorders. Their prolonged use, particularly among older adults, has raised concerns regarding a potential association with osteoporotic fractures. This review examines the current evidence linking long-term PPI therapy with fracture risk in older adults, explores the biological mechanisms proposed to explain this association, and discusses its clinical implications. Available epidemiological evidence, derived mainly from observational studies and meta-analyses, suggests a modest association between prolonged PPI use and increased risks of hip, vertebral, and overall osteoporotic fractures. Several mechanisms have been proposed, including impaired calcium absorption, altered mineral homeostasis, hypergastrinemia, micronutrient deficiencies, changes in bone remodeling and microarchitecture, and increased susceptibility to falls. However, evidence supporting these mechanisms is inconsistent, and causality remains uncertain. Although observational studies suggest an association between PPI use and fracture risk, a causal relationship has not been established. Overall, the relationship between long-term PPI use and fracture risk appears multifactorial and incompletely understood. Current evidence does not support routine discontinuation of PPIs when appropriately indicated, as their benefits generally outweigh potential skeletal risks. Instead, treatment should be individualized through regular reassessment of indication, use of the lowest effective dose, appropriate deprescribing when warranted, and assessment of fracture risk. Further prospective studies are needed to clarify causality, dose–response relationships, differences among individual PPIs, and the potential skeletal benefits of deprescribing.
Related
- Effects of percutaneous kyphoplasty with concomitant postural reduction in the treatment of acute osteoporotic vertebral compression fractures
- A study on the changes in the microstructure of trabecular bone and the biomechanical properties in patients with osteoporotic fractures and the correlation between them
- Unsupervised machine learning for clinical risk subtyping and re-fracture risk analysis in osteoporotic vertebral compression fractures.
- Correlation Between Paravertebral Muscles Degeneration and Spinopelvic Parameters in Patients With Osteoporotic Vertebral Compression Fractures.
- Comparison of Two Puncture Approaches in Robot-Assisted Percutaneous Kyphoplasty for Upper Thoracic Osteoporotic Vertebral Compression Fractures.
BibTeX
@article{oraby2026association,
title = {{Association Between Long-Term Proton Pump Inhibitor Use and the Risk of Osteoporotic Fractures}},
author = {Aseel Oraby and Boris Khalfin and Sigal Fleisher-Berkovich and Shimon Ben-Shabat},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15218398},
url = {https://www.mdpi.com/2077-0383/15/21/8398},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Association Between Long-Term Proton Pump Inhibitor Use and the Risk of Osteoporotic Fractures
AU - Aseel Oraby
AU - Boris Khalfin
AU - Sigal Fleisher-Berkovich
AU - Shimon Ben-Shabat
PY - 2026
DA - 2026/10/28
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218398
UR - https://www.mdpi.com/2077-0383/15/21/8398
AB - Proton pump inhibitors (PPIs) are among the most widely prescribed medications and remain a cornerstone in the treatment of acid-related gastrointestinal disorders. Their prolonged use, particularly among older adults, has raised concerns regarding a potential association with osteoporotic fractures. This review examines the current evidence linking long-term PPI therapy with fracture risk in older adults, explores the biological mechanisms proposed to explain this association, and discusses its clinical implications. Available epidemiological evidence, derived mainly from observational studies and meta-analyses, suggests a modest association between prolonged PPI use and increased risks of hip, vertebral, and overall osteoporotic fractures. Several mechanisms have been proposed, including impaired calcium absorption, altered mineral homeostasis, hypergastrinemia, micronutrient deficiencies, changes in bone remodeling and microarchitecture, and increased susceptibility to falls. However, evidence supporting these mechanisms is inconsistent, and causality remains uncertain. Although observational studies suggest an association between PPI use and fracture risk, a causal relationship has not been established. Overall, the relationship between long-term PPI use and fracture risk appears multifactorial and incompletely understood. Current evidence does not support routine discontinuation of PPIs when appropriately indicated, as their benefits generally outweigh potential skeletal risks. Instead, treatment should be individualized through regular reassessment of indication, use of the lowest effective dose, appropriate deprescribing when warranted, and assessment of fracture risk. Further prospective studies are needed to clarify causality, dose–response relationships, differences among individual PPIs, and the potential skeletal benefits of deprescribing.
SN - 2077-0383
ER -